Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction.
Am Heart J
; 180: 22-8, 2016 Oct.
Article
em En
| MEDLINE
| ID: mdl-27659879
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Lipoproteínas HDL
/
Infarto do Miocárdio
Tipo de estudo:
Clinical_trials
/
Prognostic_studies
Limite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Am Heart J
Ano de publicação:
2016
Tipo de documento:
Article